IRVINE, Calif., May 23, 2024 – Knobbe Martens is pleased to announce that litigation partners Sheila Swaroop and Ali Razai have been recognized as “Top Intellectual Property Lawyers” by the…
IRVINE, Calif., May 22, 2024 – Knobbe Martens is proud to announce that Managing IP has again recognized the firm’s exceptional trademark practice as part of the publication’s 2024 IP STARS rankings….
In the Managing IP article “Strengthening Ties: How US Firms Are Responding to the UPC,” partner Dr. David Schmidt shared how the firm is helping clients understand and adapt to…
Ms. Natland co-chairs INTA’s Presidential Task Force which produced the report, ‘Unlocking IP’ Susan Natland, co-chair of Knobbe Martens’ trademark and brand protection practice group, shared key research and perspective with…
Knobbe Martens partner and advertising & media practice co-chair Jonathan Hyman and associate Nickolas Taylor have authored the article “Social Media and the Law—A Warning for Brands and Content Creators,”…
Partners Sheila Swaroop and Jonathan Bachand, leaders of Knobbe’s ITC Litigation Practice Group discussed key trends at the U.S. International Trade Commission (ITC). This informative webinar discussed recent Section 337…
Litigation partner Mark Lezama spoke with Law360 for a story on the one-year anniversary of the Supreme Court’s decision in the Warhol case, and the impact the decision has had…
Jeff Van Hoosear, co-chair of the firm’s trademark and brand protection group, was quoted in Bloomberg Law, World Intellectual Property Review, IP Watchdog and The Hollywood Reporter on the significance…
April 2024 Federal Circuit Newsletter (Japanese) April 2024 Federal Circuit Newsletter (Chinese) Obviousness Analysis Does Not Consider Unclaimed Limitations In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals Usa, Inc., Appeal No….
In the latest installment of Knobbe Martens’ monthly column focused on recent noteworthy Federal Circuit decisions, partners Sean Murray and Jeremiah Helm examine the outcome of Salix Pharmaceuticals v. Norwich Pharmaceuticals….
